Analysts Set $1.75 Target Price for GTx, Inc. (GTXI)

GTx, Inc. (NASDAQ:GTXI) has earned an average broker rating score of 3.00 (Hold) from the two brokers that provide coverage for the company, Zacks Investment Research reports. Two investment analysts have rated the stock with a hold recommendation.

Analysts have set a 1 year consensus price objective of $1.75 for the company, according to Zacks. Zacks has also assigned GTX an industry rank of 74 out of 255 based on the ratings given to its competitors.

Separately, ValuEngine raised GTX from a “sell” rating to a “hold” rating in a research note on Wednesday, January 2nd.

Shares of NASDAQ GTXI traded up $0.10 during trading on Friday, reaching $1.20. 553,683 shares of the company traded hands, compared to its average volume of 2,052,906. The firm has a market capitalization of $26.46 million, a P/E ratio of -0.69 and a beta of 2.58. GTX has a 12-month low of $0.74 and a 12-month high of $25.60.

Hedge funds have recently bought and sold shares of the company. Two Sigma Advisers LP purchased a new stake in GTX during the fourth quarter valued at $36,000. Virtu Financial LLC purchased a new stake in GTX during the fourth quarter valued at $52,000. GSA Capital Partners LLP purchased a new stake in GTX during the fourth quarter valued at $85,000. Two Sigma Investments LP increased its position in GTX by 25.9% during the fourth quarter. Two Sigma Investments LP now owns 131,323 shares of the biopharmaceutical company’s stock valued at $102,000 after acquiring an additional 26,983 shares during the last quarter. Finally, Bank of America Corp DE increased its position in GTX by 2,491.6% in the fourth quarter. Bank of America Corp DE now owns 205,046 shares of the biopharmaceutical company’s stock worth $159,000 after buying an additional 197,134 shares in the last quarter. Hedge funds and other institutional investors own 13.24% of the company’s stock.

GTX Company Profile

GTx, Inc, a biopharmaceutical company, engages in the discovery, development, and commercialization of medicines for the treatment of stress urinary incontinence (SUI) and prostate cancer. It focuses on the development of selective androgen receptor modulators (SARMs) for the treatment of breast cancer, SUI, and Duchenne muscular dystrophy; and selective androgen receptor degraders to treat progressive castration-resistant prostate cancer.

See Also: Stock Selection – What is cash flow?

Get a free copy of the Zacks research report on GTX (GTXI)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for GTX Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GTX and related companies with MarketBeat.com's FREE daily email newsletter.